Elan Corporation Plc has announced an agreement to sell its 50% share in the jointly owned multiple sclerosis drug, Tysabri (natalizumab), to its partner Biogen Idec Inc for $3.25 billion upfront in cash plus double-digit, tiered royalties. ---Subscribe to MedNous to access this article--- Company News
